Jacobs Levy Equity Management’s PMV Pharmaceuticals PMVP Stock Holding History

Jacobs Levy Equity Management’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$94.5K	Sell	70,504 -109,369	-61%	-$140K	﹤0.01%	924
2026 Q1	$223K	Sell	179,873 -344,477	-66%	-$438K	﹤0.01%	907
2025 Q4	$655K	Buy	524,350 +455,682	+664%	+$610K	﹤0.01%	761
2025 Q3	$96.1K	Buy	+68,668	New	+$95K	﹤0.01%	941
2025 Q2	–	Sell	-129,914	Closed	-$142K	–	1140
2025 Q1	$142K	Sell	129,914 -409,979	-76%	-$557K	﹤0.01%	1040
2024 Q4	$815K	Sell	539,893 -165,700	-23%	-$262K	﹤0.01%	747
2024 Q3	$1.05M	Sell	705,593 -73,432	-9%	-$113K	﹤0.01%	716
2024 Q2	$1.26M	Sell	779,025 -47,679	-6%	-$86K	0.01%	686
2024 Q1	$1.41M	Buy	826,704 +397,062	+92%	+$742K	0.01%	652
2023 Q4	$1.33M	Buy	+429,642	New	+$1.14M	0.01%	675

Other funds holding PMVP

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Jacobs Levy Equity Management's PMVP Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its PMV Pharmaceuticals (PMVP) stake by 61% in Q2 2026, selling an estimated $140K and leaving 70,504 shares worth $94.5K. The position accounts for ﹤0.01% of the portfolio, ranked #924.

Jacobs Levy Equity Management first reported a position in PMVP in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.41M in Q1 2024. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

Jacobs Levy Equity Management held 70,504 shares of PMV Pharmaceuticals worth $94.5K as of Q2 2026.
Jacobs Levy Equity Management sold 109,369 PMV Pharmaceuticals shares in Q2 2026, an estimated $140K.
PMV Pharmaceuticals made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #924 holding.
Jacobs Levy Equity Management first reported a position in PMV Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Jacobs Levy Equity Management's PMV Pharmaceuticals position peaked at $1.41M in Q1 2024.
64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.